STOCK TITAN

[8-K] MOBIX LABS, INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Mobix Labs, Inc. entered an at-the-market (ATM) offering agreement with Roth Capital Partners, allowing the company to sell, from time to time, up to $15.8 million of Class A common stock through Roth as sales agent. Sales will be made under Mobix’s effective Form S-3 (File No. 333-284351), declared effective on January 24, 2025, and a prospectus supplement filed on October 21, 2025.

Roth will receive a 3.0% commission on gross proceeds, and Mobix will reimburse specified expenses up to $75,000. The company intends to use net proceeds for working capital. The ATM permits sales using methods consistent with Rule 415(a)(4), including block and privately negotiated transactions.

Mobix Labs, Inc. ha stipulato un accordo di offerta sul mercato (ATM) con Roth Capital Partners, che consente all'azienda di vendere, di volta in volta, fino a $15,8 milioni di azioni ordinarie di Classe A tramite Roth come agente di vendita. Le vendite saranno effettuate ai sensi del Form S-3 efficace di Mobix (Numero di fascicolo 333-284351), dichiarato efficace il 24 gennaio 2025, e un supplemento al prospetto presentato il 21 ottobre 2025.

Roth riceverà una commissione del 3,0% sul provento lordo, e Mobix rimborserà determinate spese fino a $75.000. L'azienda intende utilizzare i proventi netti per capitale circolante. L'ATM consente vendite utilizzando metodi conformi alla Regola 415(a)(4), inclusi blocchi e transazioni private negoziate.

Mobix Labs, Inc. firmó un acuerdo de oferta en el mercado (ATM) con Roth Capital Partners, que permite a la empresa vender, de vez en cuando, hasta $15.8 millones de acciones ordinarias de Clase A a través de Roth como agente de ventas. Las ventas se realizarán conforme al Formulario S-3 vigente de Mobix (Archivo No. 333-284351), declarado vigente el 24 de enero de 2025, y un suplemento de prospecto presentado el 21 de octubre de 2025.

Roth recibirá una comisión del 3.0% sobre los ingresos brutos, y Mobix reembolsará gastos especificados hasta $75,000. La compañía tiene la intención de usar los ingresos netos para capital de trabajo. El ATM permite ventas mediante métodos consistentes con la Regla 415(a)(4), incluidas transacciones en bloque y negociadas de forma privada.

Mobix Labs, Inc.Roth Capital Partners와 함께 시장형 공모(ATM) 계약을 체결하여 회사가 때때로 $15.8 million의 Class A 보통주를 Roth를 판매 대리인으로 통해 판매할 수 있도록 했습니다. 매출은 Mobix의 유효한 Form S-3 (파일 번호 333-284351) 하에 이루어지며, 2025년 1월 24일에 효력이 선언되었고, 2025년 10월 21일에 공모설명 보충서가 제출되었습니다.

Roth은 매출총액에 대해 3.0%의 커미션을 받게 되며, Mobix는 특정 비용을 최대 $75,000까지 상환합니다. 회사는 순매출금을 운전자본으로 사용할 예정입니다. ATM은 415(a)(4) 규칙에 따라 블록 및 사적 협상 거래를 포함한 방법으로 판매를 허용합니다.

Mobix Labs, Inc. a conclu un accord d’offre sur le marché (ATM) avec Roth Capital Partners, permettant à l’entreprise de vendre, de temps à autre, jusqu’à 15,8 millions de dollars d’actions ordinaires de classe A par l’intermédiaire de Roth en tant qu’agent de vente. Les ventes seront effectuées en vertu du formulaire S-3 efficace de Mobix (Dossier n° 333-284351), déclaré efficace le 24 janvier 2025, et d’un supplément de prospectus déposé le 21 octobre 2025.

Roth percevra une commission de 3,0% sur le produit brut, et Mobix remboursera certaines dépenses jusqu’à $75,000. L’entreprise envisage d’utiliser le produit net pour le fonds de roulement. L’ATM permet des ventes selon des méthodes conformes à la règle 415(a)(4), y compris les transactions par bloc et négociées de manière privée.

Mobix Labs, Inc. hat eine Market-at-Market (ATM) Angebotsvereinbarung mit Roth Capital Partners getroffen, die dem Unternehmen erlaubt, von Zeit zu Zeit bis zu $15,8 Millionen Class A Stammaktien durch Roth als Verkaufsdiener zu verkaufen. Die Verkäufe erfolgen gemäß Mobix’ wirksamem Formular S-3 (Datei Nr. 333-284351), das am 24. Januar 2025 wirksam geworden ist, sowie einem Prospektzusatz, der am 21. Oktober 2025 eingereicht wurde.

Roth erhält eine Bruttoprovision von 3,0% und Mobix erstattet bestimmte Ausgaben bis zu $75.000. Das Unternehmen beabsichtigt, die Nettoerlöse für Betriebskapital zu verwenden. Das ATM erlaubt Verkäufe mittels Methoden, die mit Regel 415(a)(4) übereinstimmen, einschließlich Block- und privat vereinbarten Transaktionen.

Mobix Labs, Inc. أبرمت اتفاقية عرض في السوق (ATM) مع Roth Capital Partners، مما يسمح للشركة ببيع، من وقت لآخر، حتى $15.8 مليون من أسهم فئة A العادية من خلال Roth كوكيل مبيعات. ستتم المبيعات بموجب النموذج S-3 الفعّال لـ Mobix (الملف رقم 333-284351)، الذي أصبح فعالاً في 24 يناير 2025، ومُلحق نشرة استرشادية مُقدم في 21 أكتوبر 2025.

ستتلقى Roth عمولة تبلغ 3.0% من الإيرادات الإجمالية، وتعيد Mobix تعويض نفقات محددة حتى $75,000. تعتزم الشركة استخدام العوائد الصافية لـ رأس المال العامل. يسمح الـ ATM بعمليات البيع وفقاً لقاعدة Rule 415(a)(4)، بما في ذلك المعاملات المجمّعة والمفاوضة بشكل خاص.

Mobix Labs, Inc.Roth Capital Partners 签署了市场在售(ATM)发行协议,允许公司不定期通过 Roth 作为销售代理出售最多 $15.8 百万美元 的 Class A 普通股。销售将依据 Mobix 的有效 Form S-3(档案号 333-284351)进行,该 Form 于 2025 年 1 月 24 日 生效,招股说明书增补于 2025 年 10 月 21 日提交。

Roth 将就毛收入收取 3.0% 的佣金,Mobix 将就指定费用最多报销 $75,000。公司计划将净收益用于 运营资金。该 ATM 允许使用符合 Rule 415(a)(4) 的方法进行销售,包括大宗交易和私下谈判交易。

Positive
  • None.
Negative
  • None.

Insights

Neutral setup: flexible equity access up to $15.8M.

Mobix Labs established an ATM facility with Roth Capital Partners, enabling incremental share sales under an effective S-3. The mechanism provides on-demand access to equity capital, with sales executed as market conditions permit.

Economics are straightforward: a 3.0% sales commission and expense reimbursement up to $75,000. Proceeds are designated for working capital, indicating general corporate liquidity needs rather than a specific project.

The actual impact depends on issuance pace and pricing. Key anchors disclosed include the S-3 effectiveness on January 24, 2025 and the prospectus supplement on October 21, 2025.

Mobix Labs, Inc. ha stipulato un accordo di offerta sul mercato (ATM) con Roth Capital Partners, che consente all'azienda di vendere, di volta in volta, fino a $15,8 milioni di azioni ordinarie di Classe A tramite Roth come agente di vendita. Le vendite saranno effettuate ai sensi del Form S-3 efficace di Mobix (Numero di fascicolo 333-284351), dichiarato efficace il 24 gennaio 2025, e un supplemento al prospetto presentato il 21 ottobre 2025.

Roth riceverà una commissione del 3,0% sul provento lordo, e Mobix rimborserà determinate spese fino a $75.000. L'azienda intende utilizzare i proventi netti per capitale circolante. L'ATM consente vendite utilizzando metodi conformi alla Regola 415(a)(4), inclusi blocchi e transazioni private negoziate.

Mobix Labs, Inc. firmó un acuerdo de oferta en el mercado (ATM) con Roth Capital Partners, que permite a la empresa vender, de vez en cuando, hasta $15.8 millones de acciones ordinarias de Clase A a través de Roth como agente de ventas. Las ventas se realizarán conforme al Formulario S-3 vigente de Mobix (Archivo No. 333-284351), declarado vigente el 24 de enero de 2025, y un suplemento de prospecto presentado el 21 de octubre de 2025.

Roth recibirá una comisión del 3.0% sobre los ingresos brutos, y Mobix reembolsará gastos especificados hasta $75,000. La compañía tiene la intención de usar los ingresos netos para capital de trabajo. El ATM permite ventas mediante métodos consistentes con la Regla 415(a)(4), incluidas transacciones en bloque y negociadas de forma privada.

Mobix Labs, Inc.Roth Capital Partners와 함께 시장형 공모(ATM) 계약을 체결하여 회사가 때때로 $15.8 million의 Class A 보통주를 Roth를 판매 대리인으로 통해 판매할 수 있도록 했습니다. 매출은 Mobix의 유효한 Form S-3 (파일 번호 333-284351) 하에 이루어지며, 2025년 1월 24일에 효력이 선언되었고, 2025년 10월 21일에 공모설명 보충서가 제출되었습니다.

Roth은 매출총액에 대해 3.0%의 커미션을 받게 되며, Mobix는 특정 비용을 최대 $75,000까지 상환합니다. 회사는 순매출금을 운전자본으로 사용할 예정입니다. ATM은 415(a)(4) 규칙에 따라 블록 및 사적 협상 거래를 포함한 방법으로 판매를 허용합니다.

Mobix Labs, Inc. a conclu un accord d’offre sur le marché (ATM) avec Roth Capital Partners, permettant à l’entreprise de vendre, de temps à autre, jusqu’à 15,8 millions de dollars d’actions ordinaires de classe A par l’intermédiaire de Roth en tant qu’agent de vente. Les ventes seront effectuées en vertu du formulaire S-3 efficace de Mobix (Dossier n° 333-284351), déclaré efficace le 24 janvier 2025, et d’un supplément de prospectus déposé le 21 octobre 2025.

Roth percevra une commission de 3,0% sur le produit brut, et Mobix remboursera certaines dépenses jusqu’à $75,000. L’entreprise envisage d’utiliser le produit net pour le fonds de roulement. L’ATM permet des ventes selon des méthodes conformes à la règle 415(a)(4), y compris les transactions par bloc et négociées de manière privée.

Mobix Labs, Inc. hat eine Market-at-Market (ATM) Angebotsvereinbarung mit Roth Capital Partners getroffen, die dem Unternehmen erlaubt, von Zeit zu Zeit bis zu $15,8 Millionen Class A Stammaktien durch Roth als Verkaufsdiener zu verkaufen. Die Verkäufe erfolgen gemäß Mobix’ wirksamem Formular S-3 (Datei Nr. 333-284351), das am 24. Januar 2025 wirksam geworden ist, sowie einem Prospektzusatz, der am 21. Oktober 2025 eingereicht wurde.

Roth erhält eine Bruttoprovision von 3,0% und Mobix erstattet bestimmte Ausgaben bis zu $75.000. Das Unternehmen beabsichtigt, die Nettoerlöse für Betriebskapital zu verwenden. Das ATM erlaubt Verkäufe mittels Methoden, die mit Regel 415(a)(4) übereinstimmen, einschließlich Block- und privat vereinbarten Transaktionen.

false 0001855467 0001855467 2025-10-21 2025-10-21 0001855467 MOBX:ClassCommonStockParValue0.00001PerShareMember 2025-10-21 2025-10-21 0001855467 MOBX:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassCommonStockMember 2025-10-21 2025-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 21, 2025

 

MOBIX LABS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40621   98-1591717

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1 Venture, Suite 220
Irvine, California 92618
  92618
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (949) 808-8888

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share   MOBX   Nasdaq Capital Market
Redeemable warrants, each warrant exercisable for one share of Class A Common Stock   MOBXW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On October 21, 2025, Mobix Labs, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with Roth Capital Partners, LLC (“Manager”) under which the Company may offer and sell, from time to time at its sole discretion, up to $15.8 million in shares of its Class A common stock, $0.00001 par value per share (“Common Stock”), through the Manager acting in its capacity as its sales agent.

 

Pursuant to the Agreement, sales of the Common Stock, if any, will be made under the Company’s effective Registration Statement on Form S-3 (File No. 333-284351), previously filed with the Securities and Exchange Commission on January 17, 2025 and declared effective on January 24, 2025, and the prospectus supplement relating to this offering for up to $15.8 million in shares of its Common Stock, filed on October 21, 2025 by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including privately negotiated and block transactions. The Manager will use commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The Nasdaq Capital Market to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Manager a commission of three percent (3.0%) of the gross sales proceeds of any Common Stock sold through the Manager under the Agreement, and also has provided the Manager with customary indemnification rights. The Company will also reimburse the Manager for certain specified expenses in connection with entering into the Agreement up to a maximum of $75,000. The Company intends to use the net proceeds from the offering for working capital purposes.

 

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

A copy of the legal opinion and consent of Greenberg Traurig, P.A. relating to the shares is attached hereto as Exhibit 5.1.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are filed with this report:

 

Exhibit No.   Description
1.1   At The Market Offering Agreement dated as of October 21, 2025 between the Company and Roth Capital Partners, LLC.
5.1   Opinion of Greenberg Traurig, P.A. as to the validity of shares of Mobix Labs, Inc. Class A Common Stock.
23.1   Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Mobix Labs, Inc.
   
Dated: October 21, 2025 /s/ Keyvan Samini
  Keyvan Samini
  President and Chief Financial Officer

 

 

Mobix Labs Inc

NASDAQ:MOBX

MOBX Rankings

MOBX Latest News

MOBX Latest SEC Filings

MOBX Stock Data

48.09M
44.44M
32.97%
17.8%
1.41%
Semiconductors
Semiconductors & Related Devices
Link
United States
IRVINE